Evaluating the safety and short-term equivalence of colchicine versus prednisone in older patients with acute calcium pyrophosphate crystal arthritis (COLCHICORT): an open-label, multicentre, randomised trial

医学 焦磷酸钙 强的松 不利影响 痛风 关节炎 内科学 外科
作者
Tristan Pascart,P. Robinet,Sébastien Ottaviani,Rémi Leroy,N. Segaud,Aurore Pacaud,Agathe Grandjean,H. Luraschi,Thibault Rabin,Xavier Deplanque,Pierre Maciejasz,Fabien Visade,A Mackowiak,N. Baclet,Sylvestre Maréchaux,Antoine Lefebvre,Jean‐François Budzik,Thomas Bardin,Pascal Richette,Laurène Norberciak
出处
期刊:The Lancet Rheumatology [Elsevier BV]
卷期号:5 (9): e523-e531 被引量:23
标识
DOI:10.1016/s2665-9913(23)00165-0
摘要

Background Acute calcium pyrophosphate crystal arthritis causes intense joint pain mainly affecting older people. Because guidance and evidence remain scarce, management of this disease relies on expert opinion. We therefore aimed to compare the safety and short-term equivalence of low-dose colchicine with oral prednisone in older patients with acute calcium pyrophosphate crystal arthritis. Methods We did an open-label, multicentre, randomised, trial (COLCHICORT) at six hospitals in Paris and northern France. We enrolled patients who were admitted to hospital who were 65 years or older and who presented with acute calcium pyrophosphate crystal arthritis with a symptom duration of less than 36 h. Diagnosis of calcium pyrophosphate crystal arthritis was made by the identification of calcium pyrophosphate crystals on synovial fluid analysis or typical clinical presentation (onset of joint pain and swelling). Key exclusion criteria included absence of calcium pyrophosphate crystals on synovial fluid analysis or a history of gout. Participants were randomly allocated (1:1), using a centralised electronic treatment group allocation module, to receive either colchicine 1·5 mg on day 1 and 1 mg on day 2 (ie, the colchicine group) or oral prednisone 30 mg on days 1 and 2 (ie, the prednisone group). The primary outcome was change in joint pain (measured by visual analogue scale [VAS] from 0 mm to 100 mm) at 24 h. Equivalence was determined whether the 95% CI of the between-group difference at 24 h was within the –13 mm to +13 mm margin in the per-protocol analysis. Adverse events were recorded using the National Cancer Institute Common Terminology Criteria for Adverse Events (version 4.0). This trial is completed and is registered with ClinicalTrials.gov, NCT03128905. Findings Between Feb 5, 2018, and May 7, 2022, 111 patients who were admitted to hospital were randomly assigned (57 [51%] to the colchicine group and 54 [49%] to the prednisone group). 95 (86%) of 111 patients were included in the per-protocol analysis (49 [52%] in the colchicine group and 46 [48%] in the prednisone group). The median age was 88·0 years (IQR 82·0–91·0) and 69 (73%) of 95 participants were women and 26 (27%) were men. Acute calcium pyrophosphate crystal arthritis affected mainly the knee in 46 (48%) of 95 participants, the wrist in 19 (20%), and the ankle in 12 (13%). Pain VAS at baseline was 68 mm (SD 17). At 24 h, change in pain VAS was –36 mm (SD 32) in the colchicine group and –38 mm (SD 23) in the prednisone group. The between-group difference in change in pain VAS at 24 h was –1 mm (95% CI –12 to 10), showing equivalence between the two drugs. In the colchicine group, 12 (22%) of 55 patients had diarrhoea, one (2%) had hypertension, and none had hyperglycaemia. In the prednisone group, three (6%) of 54 had diarrhoea, six (11%) had hypertension, and three (6%) had hyperglycaemia. No deaths occurred in the colchicine group; two deaths occurred in the prednisone group, which were deemed unrelated to prednisone (one due to infectious valvular endocarditis leading to heart failure, and one due to a stroke). Interpretation Colchicine and prednisone exhibit equivalent short-term efficacy for the treatment of acute calcium pyrophosphate crystal arthritis, with different safety profiles in the older population. Funding French Inter-regional Hospital Program of Clinical Research.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
嘟嘟发布了新的文献求助10
1秒前
陈开山完成签到,获得积分10
1秒前
梨理栗发布了新的文献求助10
1秒前
1秒前
alex发布了新的文献求助10
2秒前
2秒前
LaTeXer应助隐形夕阳采纳,获得50
2秒前
lw发布了新的文献求助10
3秒前
3秒前
英姑应助Janusfaces采纳,获得10
3秒前
3秒前
plasmid完成签到,获得积分10
4秒前
Ava应助咕噜咕噜咕嘟咕嘟采纳,获得10
4秒前
5秒前
SHAO应助一块司康饼采纳,获得100
5秒前
嗯哼发布了新的文献求助10
5秒前
Rondab应助mariawang采纳,获得10
7秒前
MchemG应助酷酷的紫南采纳,获得30
8秒前
1111发布了新的文献求助10
8秒前
8秒前
continue发布了新的文献求助10
9秒前
zhangtong发布了新的文献求助10
9秒前
嘟嘟完成签到,获得积分10
9秒前
wdy111应助葡萄味的果茶采纳,获得20
10秒前
悦耳代真完成签到,获得积分10
10秒前
ysx完成签到,获得积分10
10秒前
11秒前
Orange应助淡淡夕阳采纳,获得10
11秒前
11秒前
yar重新开启了yl文献应助
12秒前
13秒前
13秒前
zhoup完成签到,获得积分20
14秒前
宝海青完成签到,获得积分10
14秒前
李健应助缓慢的含双采纳,获得10
14秒前
yqb完成签到,获得积分10
15秒前
上官若男应助笑点低的不采纳,获得10
16秒前
量子星尘发布了新的文献求助10
17秒前
qifunongsuo1213完成签到,获得积分10
17秒前
chenzixin发布了新的文献求助10
17秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3988732
求助须知:如何正确求助?哪些是违规求助? 3531027
关于积分的说明 11252281
捐赠科研通 3269732
什么是DOI,文献DOI怎么找? 1804764
邀请新用户注册赠送积分活动 881869
科研通“疑难数据库(出版商)”最低求助积分说明 809021